Research Topics
| Paul HarariSummaryAffiliation: University of Wisconsin Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?P M Harari
Department of Human Oncology, University of Wisconsin School of Medicine, Madison 53792 0600, USA
J Clin Oncol 15:2050-5. 1997..Nonetheless, its use has become a common community standard of practice in the United States (US). This report examines some of the factors that may have contributed to this phenomenon...- Radiation combined with EGFR signal inhibitors: head and neck cancer focusPaul M Harari
Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, 53792, USA
Semin Radiat Oncol 16:38-44. 2006..Much remains to be learned regarding the rational integration of EGFR inhibitors into cancer treatment regimens as well as methods to optimize the selection of patients most likely to benefit from EGFR inhibitor strategies... - Promising new advances in head and neck radiotherapyP M Harari
Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
Ann Oncol 16:vi13-vi19. 2005.... 
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyondPaul M Harari
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Semin Radiat Oncol 19:63-8. 2009....- Biology of interactions: antiepidermal growth factor receptor agentsPaul M Harari
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
J Clin Oncol 25:4057-65. 2007..Many questions remain to be answered, particularly with regard to how best combine EGFR inhibitors with conventional cancer therapies, and how to select those patients (tumors) most likely to benefit from EGFR inhibition strategies... - The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer SymposiumPaul M Harari
University of Wisconsin, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S1-3. 2007 - Epidermal growth factor receptor inhibition strategies in oncologyP M Harari
University of Wisconsin Medical School, Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue K4 332, Madison, Wisconsin 53792, USA
Endocr Relat Cancer 11:689-708. 2004..It appears likely that EGFR inhibitors (and other rationally designed molecular growth inhibitors) will play a meaningful role in cancer therapy in the years to come... - Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancerPaul M Harari
University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S25-7. 2007.... - Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004Paul M Harari
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Cancer Res 10:428-32. 2004 - Radiation response modification following molecular inhibition of epidermal growth factor receptor signalingP M Harari
Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA
Semin Radiat Oncol 11:281-9. 2001..A preview of current translational research efforts and early clinical trials focused primarily on radiation interaction is provided herein... - Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiationP M Harari
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
Int J Radiat Oncol Biol Phys 49:427-33. 2001.... - Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersD L Wheeler
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Oncogene 27:3944-56. 2008..Taken together these findings suggest a rationale for the clinical evaluation of combinatorial anti-HER targeting approaches in tumors manifesting acquired resistance to cetuximab... - Multiple daily fractionation radiotherapy schedules in lung cancerC A Schulz
Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue, K4 310 CSC, Madison, WI 53792, USA
Curr Oncol Rep 3:179-84. 2001..Recent randomized trials suggest that such approaches may result not only in lowered rates of intrathoracic failure but also in improved survival... - Intensity-modulated radiation therapy: emerging cancer treatment technologyT S Hong
Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
Br J Cancer 92:1819-24. 2005..This review focuses on basic principles, and highlights the clinical implementation of IMRT in head and neck and prostate cancer... - Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapyJames S Welsh
Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA
Technol Cancer Res Treat 5:465-79. 2006.... - Clinical advancement of EGFR inhibitors in cancer therapyPrakash Chinnaiyan
Department of Human Oncology, University of Wisconsin, Madison, USA
Methods Mol Biol 327:189-202. 2006..This chapter provides an overview of EGFR inhibitors and key clinical trial results that are helping to define a future role for these molecular agents in cancer treatment... - EGFR-targeting monoclonal antibodies in head and neck cancerIgor Astsaturov
Fox Chase Cancer Center, Philadelphia, PA, USA
Curr Cancer Drug Targets 6:691-710. 2006.... - Planned postradiotherapy neck dissection: Rationale and clinical outcomesGregory K Sewall
Division of Otolaryngology Head and Neck Surgery, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792, USA
Laryngoscope 117:121-8. 2007.... - Anti-EGFR therapy update: clinical experience and adverse event insightsPaul M Harari
Department of Human Oncology, University of Wisconsin, Madison, Wisconsin 53792, USA
Oncology (Williston Park) 20:3-4. 2006 - Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neckNadine P Connor
Department of Otolaryngology Head and Neck Surgery, University of Wisconsin Medical School, and William S Middleton Memorial Veterans Hospital, Madison, WI 53792 7375, USA
Int J Radiat Oncol Biol Phys 65:1051-62. 2006..Head-and-neck radiotherapy is associated with significant morbidities. Our purpose was to document impact of morbidities by use of multiple objective measures and health-related quality of life (HR-QOL)... - Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabDesmond Curran
Omega Research, Dublin, Ireland
J Clin Oncol 25:2191-7. 2007..In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab... - Insulin-like growth factor-I receptor signaling blockade combined with radiationGregory W Allen
Department of Human Oncology, School of Medicine and Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA
Cancer Res 67:1155-62. 2007..In summary, these results validate IGF-IR signal transduction blockade as a promising strategy to improve radiation therapy efficacy in human tumors, forming a basis for future clinical trials... - Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directionsSøren M Bentzen
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4 316 Clinical Sciences Center, Madison, WI 53792, USA
Nat Clin Pract Oncol 4:172-80. 2007..Further clinical progress in this field will require hypothesis-driven trials to ensure efficient identification of treatments with the most favorable risk:benefit ratio... - Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparisonC Wesley Hodge
Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:1032-41. 2007.... - Bridging gaps in multidisciplinary head and neck cancer care: nursing coordination and case managementPeggy A Wiederholt
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S88-91. 2007.... - Clinical application of EGFR inhibitors in head and neck squamous cell cancerIgor Astsaturov
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Cancer Treat Res 139:135-52. 2008 - Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research programChristine H Chung
Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
Int J Radiat Oncol Biol Phys 69:S67-78. 2007..In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG... - Beware the swing and a miss: baseball precautions for conformal radiotherapyPaul M Harari
Int J Radiat Oncol Biol Phys 70:657-9. 2008 - EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neckRanee Mehra
Department of Human Oncology, University of Wisconsin School of Medicine, 600 Highland Avenue K4 336, Madison, WI 53792, USA
Curr Oncol Rep 10:176-84. 2008..These promising results have prompted further study of EGFR inhibitors with radiation and cytotoxic chemotherapy to further increase the benefit of treatment for SCCHN... - Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancerTim J Kruser
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Int J Radiat Oncol Biol Phys 72:534-42. 2008..To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts... - Parotidectomy: ten-year review of 237 cases at a single institutionDavid C Upton
Department of Surgery, Division of Otolaryngology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
Otolaryngol Head Neck Surg 136:788-92. 2007.... - Augmentation of radiation response with the vascular targeting agent ZD6126Tien Hoang
Hematology/Oncology Division, Ohio State University College of Medicine, Columbus, OH, USA
Int J Radiat Oncol Biol Phys 64:1458-65. 2006..These results complement recent reports suggesting the potential value of combining radiation with vascular targeting/antiangiogenic agents... - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckJames A Bonner
Department of Medicine, University of Alabama, Birmingham, USA
N Engl J Med 354:567-78. 2006.... - Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitorShyhmin Huang
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792-0600, USA
Cancer Res 64:5355-62. 2004..This approach suggests potential new strategies to maximize effective target inhibition, which may improve the therapeutic ratio for anti-EGFR-targeted therapies in developing clinical trials... - Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?Paul M Harari
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
Int J Radiat Oncol Biol Phys 58:976-83. 2004..To highlight some of the preclinical data that examine the interaction of epidermal growth factor receptor (EGFR) inhibitors with radiotherapy and chemotherapy... - Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendationsPaul M Harari
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
Curr Probl Cancer 28:7-40. 2004 - Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedulesJack F Fowler
Department of Human Oncology K4/316, University of Wisconsin, 600 Highland Ave, Madison, WI 53792, USA
Radiother Oncol 69:161-8. 2003..The 'acute/ tolerance zone' then turns out to be 59-61 Gy10 for radiation-only treatments. Further information about the decrement caused by concurrent head-and-neck cancer chemoradiotherapy, possibly 3-5 Gy10, is required... - Helical tomotherapy: an innovative technology and approach to radiation therapyJames S Welsh
Department of Human Oncology, University of Wisconsin, School of Medicine, 600 Highland Avenue, Madison, WI 53792, USA
Technol Cancer Res Treat 1:311-6. 2002..Based on radiobiological principles that exploit the physical advantages of helical tomotherapy, several dosimetric and clinical investigations are underway... - Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumorsPaul M Harari
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center and School of Medicine, Madison, WI 53792, USA
Semin Radiat Oncol 13:3-12. 2003..However, we lack randomized trials that directly compare operative versus nonoperative treatment approaches and thus have consciously neglected review of the surgical series for purposes of this article... - Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockadeShyh-Min Huang
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792-0600, USA
Mol Cancer Ther 1:507-14. 2002..Taken together, these results provide evidence that C225 can suppress tumor-induced neovascularization and metastasis in SCC of the head and neck... - Cetuximab (Imclone/Merck/Bristol-Myers Squibb)Merrill S Kies
University of Texas MD Anderson Cancer Center, Houston 77030, USA
Curr Opin Investig Drugs 3:1092-100. 2002..In May 2002, Lehman Brothers predicted global peak sales of US $2 billion [454652], while in the same month, Bear Stearns estimated that sales for Merck KGaA would reach 285 million Euros in 2007 [453500]... - Epidermal growth factor receptor modulation of radiation response: preclinical and clinical developmentPaul M Harari
Department of Human Oncology, University of Wisconsin School of Medicine, Madison 53792, USA
Semin Radiat Oncol 12:21-6. 2002..This report focuses primarily on the capacity of EGFR inhibitors to modulate cellular and overall tumor response to ionizing radiation... - Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)Shyh-Min Huang
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Cancer Res 62:4300-6. 2002.... - The impact of daily setup variations on head-and-neck intensity-modulated radiation therapyTheodore S Hong
Department of Human Oncology, University of Wisconsin Medical School, University Hospital and Clinics, 600 Highland Avenue K4/332, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 61:779-88. 2005.... - Parotid area lymph node metastases from cutaneous squamous cell carcinoma: implications for diagnosis, treatment, and prognosisTheodore S Hong
Department of Human Oncology, University of Wisconsin Hospital and Clinics, 600 Highland Avenue K4/332, Madison, WI 53792, USA
Head Neck 27:851-6. 2005..Selective neck dissection or radiation may be warranted at the time of parotidectomy. This combined approach is associated with high locoregional control rates and is generally well tolerated... - Precautions in the use of intensity-modulated radiation therapyJames S Welsh
Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Technol Cancer Res Treat 4:203-10. 2005..Here we discuss some of the precautions worthy of consideration when using IMRT and how these might be addressed in routine practice... - Intensity-modulated radiation therapy in the management of head and neck cancerTheodore S Hong
Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
Curr Opin Oncol 17:231-5. 2005..However, mature clinical data remains relatively limited and specific aspects regarding the practice of head and neck IMRT remain heterogeneous... - Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)Prakash Chinnaiyan
Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Cancer Res 65:3328-35. 2005..These data suggest that the erlotinib/radiation combination represents a strategy worthy of further examination in clinical trials... - Modulation of radiation response by histone deacetylase inhibitionPrakash Chinnaiyan
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792-0600, USA
Int J Radiat Oncol Biol Phys 62:223-9. 2005..We are examining the capacity of HDAC inhibitors to modulate radiation response and tumor control in animal xenograft model systems to strengthen the rationale for future clinical trial exploration... - Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockadeJing Li
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792-0600, USA
Int J Radiat Oncol Biol Phys 62:1477-85. 2005..These data suggest that molecular inhibition of VEGFR2 alone, and in combination with radiation, can enhance tumor response through molecular targeting of tumor vasculature... - Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and RasPrakash Chinnaiyan
Department of Human Oncology, University of Wisconsin Medical School, Madison, 53792-0600, USA
Semin Radiat Oncol 16:59-64. 2006..These approaches reviewed herein hold promise for improved radiation therapy efficacy and, ultimately, improved patient outcome... - Biologic basis for combining drugs with radiationGeorge D Wilson
Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
Semin Radiat Oncol 16:2-9. 2006.... 
Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapyMark J Been
Department of Surgery, Division of Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
Laryngoscope 118:1377-82. 2008..The purpose of this study was to conduct an institutional review analyzing the correlation between tumor volume and locoregional control of oropharyngeal squamous cell cancer treated with primary radiotherapy...- IntroductionPaul M Harari
Semin Radiat Oncol 16:1. 2006 - Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibitionPrakash Chinnaiyan
Department of Human Oncology, University of Wisconsin, Madison, WI 53792-0600, USA
Int J Cancer 118:1041-50. 2006.... - ACCO: ASCO core curriculum outlineHyman B Muss
Education, Science and Career Development, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 23:2049-77. 2005 - Megavoltage computed tomography: an emerging tool for image-guided radiotherapyTheodore S Hong
Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
Am J Clin Oncol 30:617-23. 2007..In this study, we assessed the image-quality, absorbed radiation doses, and clinical practicality of MVCT from our helical tomotherapy prototype unit...
Research Grants
- EGFR/Radiation Responses and Resistance InteractionsPaul Harari; Fiscal Year: 2007..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..
- EGFR/Radiation Response and Resistance InteractionsPaul M Harari; Fiscal Year: 2010..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..